MediciNova, Inc. MNOV
1.42 USD -0.05 (-3.40%)
Nov 10, 2026, 3:05 PM EST
1.41 Day range 1.55
1.22 52-week range 3.90
- YTD
- +8.40%
- 1 year
- +0.71%
News
benzinga.com MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
benzinga.com MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles MediciNova reported Phase 2 topline trial results for tipelukast in treating NAFLD and hypertriglyceridemia.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
benzinga.com MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and…
benzinga.com MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies…
benzinga.com This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
benzinga.com Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
- benzinga.com MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad…
benzinga.com This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday 
benzinga.com This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings page for more info. Consider buying COHU stock.- benzinga.com HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10 HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $10.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.- benzinga.com MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the…
- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
benzinga.com MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful…- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
benzinga.com MediciNova Completes Patient Enrollment In Its Phase 2 MN-001-NATG-202 Trial Of MN-001 (Tipelukast) For Hypertriglyceridemia And Non-alcoholic Fatty Liver Disease Due To Type 2 Diabetes, Top-Line Data Are Expected By The Summer Of 2026 The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
benzinga.com Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research.- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
- benzinga.com MediciNova Completes Patient Enrollment In Phase 2/3 Clinical Trial, COMBAT-ALS For Treatment Of Amyotrophic Lateral Sclerosis MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful…
- benzinga.com MediciNova Issues Shareholder Update; Secures $30M SEPA To Advance R&D As COMBAT-ALS Trial Hits Enrollment Target; NIH-Funded EAP And MN-001 Diabetes Study Near Completion MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), provides a…
- benzinga.com MediciNova Q2 EPS $(0.07) Beats $(0.10) Estimate, Sales $134.599K MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 26.32 percent. This is a 40 percent decrease over losses of $(0.05) per…
- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
- benzinga.com B. Riley Securities Maintains Buy on MediciNova, Lowers Price Target to $5 B. Riley Securities analyst Mayank Mamtani maintains MediciNova (NASDAQ:MNOV) with a Buy and lowers the price target from $6 to $5.
- benzinga.com MediciNova Q1 EPS $(0.06) Beats $(0.14) Estimate MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by 57.14 percent. This is unchanged from the same period last year.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market…
- benzinga.com Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 258 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 297 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's morning trading, 152 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning saw 454 companies set new 52-week lows.
- benzinga.com 68 Biggest Movers From Wednesday Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the morning session on Thursday, 152 stocks hit new 52-week lows.